09:51 AM EST - Arch Biopartners Inc. : Announced that the Cincinnati Veterans Affairs Medical Center will conduct an investigator initiated Phase I human trial to evaluate the safety and pharmacokinetic profile of AB569, the Company's inhalation drug candidate for treating antibiotic-resistant bacterial infections in the lungs. Arch Biopartners Inc.
shares V.ARCH are trading up $0.05 at $0.44.
